跳至主要内容
临床试验/NCT02688153
NCT02688153已完成不适用

A Randomized Comparison of the EDWARDS INTUITY Valve System anD commErcially Available Aortic Bioprostheses in Subjects uNdergoing surgiCal Aortic Valve replacEment

Edwards Lifesciences2 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2012年10月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
120
试验地点
2
主要终点
Average Amount of Time Subject Spent on Cardiopulmonary Bypass

研究概览

简要总结

The study purpose is to compare the EDWARDS INTUITY valve system with commercially available stented aortic bioprostheses, in patients requiring aortic valve replacement surgery with coronary artery bypass.

详细描述

This is a randomized study comparing the cross-clamp time (XCT) and cardiopulmonary bypass time (CPBT) of the EDWARDS INTUITY valve system with any commercially available stented aortic bioprosthesis, in patients with logistic EuroSCORE 1 ≥ 6 undergoing elective surgical aortic valve replacement surgery with concomitant coronary bypass grafts.

Additionally, the aim is to gather sufficient data to quantify the effect size of short term patient benefit outcomes previously identified from literature and finally to explore additional healthcare resource utilization or health economic endpoints.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • ≥18 years of age
  • aortic stenosis / mixed aortic stenosis and aortic insufficiency
  • SAVR+CABG (1-4 distal anastomoses)
  • Log. EuroSCORE ≥6
  • NYHA Class ≥II
  • Exclusion (i.a.):
  • pure aortic insufficiency
  • pre-existing prosthetic heart valve or ring
  • congenital true bicuspid / unicuspid aortic valve
  • LVEF <20%

排除标准

  • 未提供

研究组 & 干预措施

EDWARDS INTUITY

Active Comparator

EDWARDS INTUITY Valve System, Model 8300A

干预措施: EDWARDS INTUITY (Device)

Stented aortic bioprostheses

Active Comparator

Stented aortic bioprostheses

干预措施: Stented aortic bioprostheses (Device)

结局指标

主要结局

Average Amount of Time Subject Spent on Cardiopulmonary Bypass

时间窗: At time of surgery, an average of 2 hours

Cardiopulmonary bypass time is the amount of time that the patient's blood circulates through an artificial heart and lung machine during cardiac surgery.

Average Subject Time Spent on Cardiopulmonary Cross Clamp

时间窗: At time of surgery, an average of 1.5 hours

Cardiopulmonary cross clamp time is the amount of time that the patient's aorta (blood vessel) is clamped by a surgical instrument used in cardiac surgery. This allows the normal blood flow to be sent to an artificial heart and lung machine to keep it at a constant temperature and oxygen level.

次要结局

  • Subjects Who Experienced Major Bleeding Over Time.(30 days, 3 Months, 6 Months, 1 Year, 2 Years.)
  • Conversion of Edwards INTUITY Surgical Aortic Valve to Control During Surgery.(Prior to Surgery)
  • Subjects Who Received a Permanent Pacemaker Over Time.(30 days, 3 Months, 6 Months, 1 Year, 2 Years.)
  • Subject's Average Mean Gradients (mmHg) Measurements Over Time.(30 days, 3 Months, 6 Months, 1 Year, 2 Years.)
  • Subject's Effective Orifice Area Index (EOAI) Measurement Over Time.(30 days, 3 months, 6 months, 1 year, 2 year)
  • Subjects Who Required a Thoracic Resternotomy Over Time(30 days, 3 Months, 6 Months, 1 Year, 2 Years.)
  • Subjects With Endocarditis Over Time(30 days, 3 Months, 6 Months, 1 Year, 2 Years.)
  • Subjects With a Thromboembolism Over Time(30 days, 3 Months, 6 Months, 1 Year, 2 Years.)
  • Subjects Who Died Intraoperatively(Surgery)
  • Subject's Effective Orifice Area (EOA) Measurement Over Time.(30 days, 3 months, 6 months, 1 year, 2 year)
  • Subjects With a Major Paravalvular Leak (OPC) Over Time(30 days, 3 Months, 6 Months, 1 Year, 2 Years.)
  • Subjects With a Cerebral Vascular Accident or Permanent Stroke Over Time(30 days, 3 Months, 6 Months, 1 Year, 2 Years.)
  • Subjects With a Cardiac Tamponade Over Time(30 days, 3 Months, 6 Months, 1 Year, 2 Years.)
  • Amount of Aortic Valvular Regurgitation Over Time.(30 days, 3 months, 6 months, 1 year, 2 year)
  • Subjects With Renal Failure Over Time(30 days, 3 Months, 6 Months, 1 Year, 2 Years.)
  • Subjects With a Myocardial Infarction Over Time(30 days, 3 Months, 6 Months, 1 Year, 2 Years.)
  • Number of Participants With Change From Baseline in New York Heart Association (NYHA) Class at 2 Years.(Baseline and 2 Years)
  • Subject's Average Peak Gradients (mmHg) Measurements Over Time.(30 days, 3 months, 6 months, 1 year, 2 year)
  • Subjects With a Cardiac Reoperation for Any Reason Over Time(30 days, 3 Months, 6 Months, 1 Year, 2 Years.)
  • Subject's Average Score SF-12 - Quality of Life Questionnaire Over Time(Baseline, 30 days, 3 Months, 6 Months, 1 Year, 2 Years.)
  • Subjects Who Experienced Respiratory Failure Over Time(30 days, 3 Months , 6 Months, 1 Year, 2 Years.)
  • Subjects With a Deep Sternal Would Infection Over Time(30 days, 3 Months, 6 Months, 1 Year, 2 Years.)
  • Subject's Average Score on the EQ-5D- Quality of Life Questionnaire Over Time(Baseline, 30 days, 3 Months, 6 Months, 1 Year, 2 Years.)
  • Health Care Utilization(Day of surgical procedure through discharge from the hospital, an average of 2 weeks)
  • Subject's Average Score on the KCCQ - Quality of Life Questionnaire Over Time(Baseline, 30 days, 3 Months, 6 Months, 1 Year, 2 Years.)

研究者

发起方
Edwards Lifesciences
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验